MedTrace Logo

Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe

NCT05194579 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2024-08-12

Study results available
· View outcomes & findings →

Summary

This will be an open-label, randomized, 2-treatment, 2-period, crossover single-dose study in approximately 134 healthy adult participants. Participants will be randomized into 2 sequences of treatment as described in the following table of Intervention Groups and Duration.

Conditions

  • Healthy Volunteers

Interventions

COMBINATION_PRODUCT

PF-06881894 by on-body injector

PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection

COMBINATION_PRODUCT

PF-06881894 by prefilled syringe

PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2022-08-10
Completion
2022-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05194579 on ClinicalTrials.gov